HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Longboard Pharmaceuticals, maintaining a price target of $60. Analyst Patrick Trucchio remains optimistic about the company's prospects.
August 22, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Longboard Pharmaceuticals, maintaining a price target of $60. Analyst Patrick Trucchio remains optimistic about the company's prospects.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100